Autologous CD19/CD22 Chimeric Antigen Receptor T-cells for Minimal Residual Disease

"This study is not currently looking for new patients, as the last update occurred on July 18th, 2022. The study was originally posted on November 30th, 2020. If you are exploring other studies, 3971 trials are actively enrolling participants with minimal residual disease and 928 trials for Autologous CD19/CD22 Chimeric Antigen Receptor T-cells are also recruiting."

"This study is currently admitting 30 patients that meet the following criteria: Aged 6 months to 70 years old, having minimal residual disease, and total bilirubin levels below 1.5 mg/dL (except for patients with Gilbert syndrome, whose total bilirubin must be below 3.0 mg/dL). Additional requirements include an ejection fraction of 50% or above as determined by echocardiogram or multigated acquisition scan, no significant ECG findings, relapsed or refractory B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's"

"CAR-T therapy that targets CD19 and CD22 receptors is commonly used to treat multiple sclerosis but can also be applied to various other conditions, such as mixed-cell type lymphoma, leukemia, myelocytic, acute, retinoblastoma."

"The current recruitment drive for this clinical trial is targeting patients that are older than 6 months but younger than 70 years old."

"Unfortunately, this particular trial is not looking for new patients at the moment. It was originally posted on November 30th 2022 but has not been updated since July 18th of the same year. Although, there are nearly 5000 other trials that are currently enrolling participants."

"Currently, there are 928 studies being conducted on Autologous CD19/CD22 Chimeric Antigen Receptor T-cells. Out of those, 165 are in Phase 3. Most of the research is taking place in Philadelphia, Pennsylvania; however, there are 28613 locations running these types of studies."